GleamWall
中文EN

AXIM AXIM BIOTECHNOLOGIES, INC.

Pharmaceutical Preparations · OTC · SEC CIK 1514946 · Fiscal year ends 12/31

Financial factors as of 2022-09-30 (2022Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-89.0%
TTM net income YoY-29.0%
TTM EPS YoY282.5%
Revenue 3-yr CAGR-67.8%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-182,235.4%
Net margin-218,733.8%
FCF margin—
EBITDA margin-142,796.3%

Returns

ROE-10,021.6%
ROA-143.0%
ROIC (approx.)—
Asset turnover0.00x

Leverage & solvency

Liabilities / assets197.8%
Debt / equity—
Current ratio0.08x
Interest coverage-7.07x

Cash quality & payout

Operating cash flow / net income0.19x
Accruals ratio-116.1%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20232023-12-31FY20222022-12-31
Income statement
Revenue$39,518$8,875
R&D expense$125,496$153,697
SG&A expense$2.24M$4.08M
Operating income-$2.75M-$4.65M
Interest expense$140,000$261,537
Pretax income-$8.06M-$6.24M
Income tax$0$0
Net income-$8.06M-$6.24M
EBITDA-$2.32M-$4.23M
EPS (basic)-0.04-0.04
EPS (diluted)-0.04-0.04
Banking
Noninterest expense$0$177,500
Balance sheet
Cash & equivalents$156,457$47,282
Current assets$156,457$103,979
PP&E, net$134,067$93,840
Intangibles—$3.99M
Total assets$4.12M$4.21M
Current liabilities$5.98M$3.39M
Short-term debt$94,829$19,789
Long-term debt$137,044—
Total debt$231,873—
Total liabilities$11.78M$9.04M
Shareholders' equity-$7.66M-$4.83M
Net debt$75,416—
Shares outstanding245.93M192.44M
Cash flow statement
Operating cash flow-$1.03M-$2.04M
Capital expenditure$0$8,710
Free cash flow-$1.03M-$2.05M
Investing cash flow$0-$8,710
Financing cash flow$1.14M$1.65M
Depreciation & amortization$427,019$426,126
Stock-based compensation$197,727$1.11M

Free plan shows the latest 2 periods; Pro shows all 13 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.